Cardio Diagnostics Holdings, Inc.
CDIO
NASDAQ·Healthcare·Biotechnology·Mkt cap $5.8M
$1.92
▲ +1.05%
P/E
—
Mkt Cap
$5.8M
52-Wk Range
$0.97–$7.91
52-Week Range
$0.97 - $7.91
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 55.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary epigenetics technology platform for cardiovascular disease detection
- Innovative three-year symptomatic CHD risk prediction capabilities
- Strong intellectual property portfolio in epigenetic biomarker development
- Positioned at intersection of precision medicine and preventive cardiology trends
Bear Case
1 risk
- High volatility (beta 2.2). Larger-than-normal price swings expected.
Growth
Stable outlook
Rising demand for non-invasive cardiovascular disease screening and risk assessment
Value
Valuation data unavailable
Momentum
Stable
-1.5% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CDIO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 6, 2026
AUG 7, 2026
Most recent quarter reported revenue of $5.4K (-28% YoY). Reported EPS of -$0.51. Gross margin 0.0%.
Reported EPS · last 4Q
0 of 1 beats
Q3 26
—
Revenue trend · last 8Q
—
—
-94%
-5%
-57%
-21%
+185%
-28%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$6.6K
$4.5K
$940
$7.5K
$2.9K
$3.6K
$2.7K
$5.4K
Margins · last 8Q
Gross
0.0%
Profit
-28012.5%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How CDIO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related